New Update on Clinical Development of RG7800
Genentech recently provided an update on the clinical development of RG7800, an investigational SMN2 splicing modifier that is being studied as a potential treatment for spinal muscular atrophy (SMA): “Moonfish is studying RG7800, an investigational SMN2 splicing modifier that Genentech (Roche) is developing for the treatment of spinal muscular atrophy (SMA). This program is in
New Update on Clinical Development of RG7800 Read More »

